Phylogenetic Status of the Turkish Red Fox (Vulpes vulpes), based on Partial Sequences of the Mitochondrial Cytochrome b Gene

Genetic diversity and multiple mitochondrial phylogroups of the red fox have been revealed from scattered locations in previous studies. There is a still lack of information about the genetic diversity and phylogeographic structure of the red fox in Asia Minor. We investigated the genetic diversity in the Turkish red fox using a part of the cytochrome b mitochondrial gene (375 bp), and attempted to evaluate the phylogeographic structure in various geographic ranges of the species with the use of sequences available from the GenBank from various geographic origins and our data. Bayesian and Network analyses of the cytochrome b sequences from Turkey and GenBank suggested that the red fox is divided into four main phylogroups. They are grouped accordingly: Group 1 (SW Anatolia, Turkey and Hokkaido, Japan), Group 2 (Eurasia and North America), Group 3 (only North America), and Group 4 (Vietnam). The majority of Turkish haplotypes grouped with those of Eurasia. Despite the great distance between the localities, two haplotypes from SW Anatolia, Turkey grouped with previously reported haplotypes from Hokkaido, Japan. The present study shows that the Turkish red fox is nested within two main phylogroups and exhibits a high genetic diversity

Lamivudine Treatment Failure Risks in Chronic Hepatitis B Patients with Low Viral Load

Aim: To analyze the risk factors of lamivudine treatment failure (LTF) for the long-term use in patients with low viral load (LVL). Material and Methods: In this multicenter study, 548 antiviral nave noncirrhotic adult patients with LVL (for HBeAg+ patients HBV DNA = 100,000 copies/ml had 54.8 and 67.3% LTF rates at the end of the 5th year, respectively. Logistic regression analysis of risk factors showed HBeAg+, hepatic activity index, HBV DNA, virological response at 6 months and duration of follow-up were independent predictors for LTF (p values were 0.001, 0.008, 0.003, 0.020 and 0.003, respectively). Conclusion: Similar to patients with HVL, first-line lamivudine therapy is not efficient for long-term use in patients with LVL. LTF risk is so high even in the absence of worse predictive factors. (C) 2013 S. Karger AG, Base

Lamivudine Treatment Failure Risks in Chronic Hepatitis B Patients with Low Viral Load

Aim: To analyze the risk factors of lamivudine treatment failure (LTF) for the long-term use in patients with low viral load (LVL). Material and Methods: In this multicenter study, 548 antiviral nave noncirrhotic adult patients with LVL (for HBeAg+ patients HBV DNA = 100,000 copies/ml had 54.8 and 67.3% LTF rates at the end of the 5th year, respectively. Logistic regression analysis of risk factors showed HBeAg+, hepatic activity index, HBV DNA, virological response at 6 months and duration of follow-up were independent predictors for LTF (p values were 0.001, 0.008, 0.003, 0.020 and 0.003, respectively). Conclusion: Similar to patients with HVL, first-line lamivudine therapy is not efficient for long-term use in patients with LVL. LTF risk is so high even in the absence of worse predictive factors. (C) 2013 S. Karger AG, Base